SHATTUCK LABS INC
STTKNASDAQTrading Snapshot
- Day Range
- $6.50 – $6.57
- 52-Week Range
- $1.70 – $8.33
- Volume
- $2.49B
- Avg Volume
- $2.72B
- Shares Outstanding
- 90.4M
- Next Earnings
- Dec 10, 2026
Fundamentals Snapshot
- Annual Revenue
- $1M
- Last Q Revenue
- $227,341
- P/E Ratio
- -12.5
- P/S Ratio
- 575.7x
- EPS (TTM)
- $-0.41
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +104.1%
Why Investors Own STTK
- ✓High-growth profile — revenue up +25.4% YoY with expanding US Equity exposure.
- ✓Healthy economics — 39% gross margin and 5% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
SHATTUCK LABS INC
STTK
StockOtter · stockotter.spaceAbout SHATTUCK LABS INC
Shattuck Labs, Inc. operates as a biotechnology firm based in the United States, currently at the clinical development stage. Its core mission is to create innovative therapeutics designed to combat both cancer and autoimmune diseases. The company's leading experimental compound, SL-172154, is presently undergoing Phase 1 clinical assessment for the treatment of ovarian, fallopian tube, and peritoneal cancers. Furthermore, Shattuck Labs is advancing another product candidate, SL-279252, which is also in Phase 1 trials for patients afflicted with advanced solid tumors and lymphoma. Established in 2016, the company maintains its corporate headquarters in Austin, Texas.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
3,750,000 Shares in Shattuck Labs, Inc. $STTK Purchased by Frazier Life Sciences Management L.P.
Frazier Life Sciences Management L.P. bought a new position in shares of Shattuck Labs, Inc. (NASDAQ: STTK) during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commissio
BlackRock Inc. Invests $27.32 Million in Shattuck Labs, Inc. $STTK
BlackRock Inc. purchased a new stake in Shattuck Labs, Inc. (NASDAQ: STTK) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 3,93
Shattuck Labs Announces Participation in Upcoming September Investor Conferences
AUSTIN, Texas and DURHAM, N.C., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potential first-in-cla
Shattuck Labs: A Receptor-Side Bet On The TL1A Boom
Shattuck Labs pivots to immunology, focusing on DR3-targeted therapies for IBD, notably SL-325, after discontinuing its oncology program. SL-325's Phase 1 data show strong safety, low immunogenicity (3.7% ADA rate), and
What Shattuck Labs Stock Topped the Market on Monday
One of them initiated coverage. The company has a very promising lead drug candidate.
Shattuck Labs, Inc. (STTK) is a Great Momentum Stock: Should You Buy?
Does Shattuck Labs, Inc. (STTK) have what it takes to be a top stock pick for momentum investors? Let's find out.